Interleukin-1β, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients
Authors:
- 21 September 2020
- journal article
- research article
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 190 (2) , 631-638
Abstract
Background This study was to investigate the value of 10 serum inflammatory cytokines for predicting clinical response to celecoxib in ankylosing spondylitis (AS) patients. Methods Totally, 103 active AS patients who underwent celecoxib treatment for 12 weeks were enrolled. Then, pre-treatment serum TNF-α, IL-1β, IL-6, IL-8, IL-17A, IL-21, IL-23, IL-32, ICAM-1, and VEGF were detected by enzyme-linked immunosorbent assay. Besides, the ASAS 20 response was assessed at week 2 (W2), week 6 (W6), and week 12 (W12). Based on the ASAS 20 response at W12, patients were divided into responders and non-responders. Results After celecoxib treatment, 53 (51.3%), 58 (56.3%), and 60 (58.3%) patients achieved ASAS 20 response at W2, W6, and W12, respectively. Furthermore, IL-1β (P = 0.019), IL-6 (P = 0.004), and IL-17A (P = 0.007) levels were higher, while TNF-α (P = 0.086), IL-8 (P = 0.143), IL-21 (P = 0.687), IL-23 (P = 0.329), IL-32 (P = 0.216), ICAM-1 (P = 0.119), and VEGF (P = 0.732) levels were similar in responders compared with non-responders. Subsequent multivariate logistic regression analysis revealed that among these inflammatory cytokines, only IL-6 (P = 0.019) independently predicted higher ASAS 20 response to celecoxib at W12, and it had a fair value for predicting ASAS 20 response to celecoxib at W12 (area under the curve: 0.666, 95% confidence interval: 0.561–0.771) by receiver-operating characteristic curve analysis. Conclusion Serum IL-1β, IL-6, and IL-17A serve as indicators for predicting clinical response to celecoxib in AS patients, which may assist with the optimization of personalized treatment.Keywords
This publication has 16 references indexed in Scilit:
- Pain in ankylosing spondylitis: a neuro-immune collaborationNature Reviews Rheumatology, 2017
- Role of Th1/Th2 cytokines in the diagnosis and prognostic evaluation of ankylosing spondylitisGenetics and Molecular Research, 2017
- Efficacy and Safety of Celecoxib in Chinese Patients with Ankylosing Spondylitis: A 6-Week Randomized, Double-Blinded Study with 6-Week Open-Label Extension TreatmentCurrent Therapeutic Research, 2014
- Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative studyScandinavian Journal of Rheumatology, 2014
- CelecoxibDrugs, 2011
- Serum cytokine levels and periodontal parameters in ankylosing spondylitisJournal of Periodontal Research, 2011
- Pathogenesis of ankylosing spondylitisNature Reviews Rheumatology, 2010
- The safety of celecoxib in ankylosing spondylitis treatmentExpert Opinion on Drug Safety, 2008
- Issues in the Treatment of Ankylosing Spondylitis with Non-Steroidal Anti-Inflammatory DrugsWiener Medizinische Wochenschrift, 2008
- Ankylosing spondylitisThe Lancet, 2007